SCHEMBL16553554

SCHEMBL16553554

CC(C)Cn1nc(C(=O)O)cc1-c1ccc(-c2ccc(CO)c(S(C)(=O)=O)c2)cc1

nearest known ligand 0.77

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 6/20 0.77
MARS1 P56192 7/20 0.41
MDM2 Q00987 4/20 0.38
MCL1 Q07820 4/20 0.38
RXRA P19793 2/20 0.37
NR1H3 Q13133 2/20 0.37
BCL2 P10415 3/20 0.35
SLC16A3 O15427 1/20 0.35
SLC16A1 P53985 1/20 0.35
PTGS2 P35354 1/20 0.34
RPA1 P27694 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17943738 0.94 NR1H2 (0.71) NR1H2MARS1MDM2MCL1BCL2
SCHEMBL29496569 0.89 NR1H2 (0.73) NR1H2MARS1RXRANR1H3PTGS2
SCHEMBL16566131 0.89 NR1H2 (0.73) NR1H2MARS1RXRANR1H3PTGS2
SCHEMBL16566090 0.87 NR1H2 (1.00) NR1H2RXRANR1H3PTGS2
SCHEMBL16566124 0.87 NR1H2 (0.70) NR1H2RXRANR1H3SLC16A3SLC16A1
SCHEMBL29496560 0.87 NR1H2 (0.70) NR1H2RXRANR1H3SLC16A3SLC16A1
SCHEMBL17970790 0.86 NR1H2 (0.72) NR1H2RXRANR1H3PTGS2
SCHEMBL16553481 0.86 NR1H2 (0.58) NR1H2MARS1MDM2MCL1BCL2
SCHEMBL25878810 0.85 NR1H2 (0.68) NR1H2RXRANR1H3PTGS2
SCHEMBL16553546 0.84 NR1H2 (0.67) NR1H2RXRANR1H3PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212127-A1 LIVER X RECEPTOR (LXR) MODULATORS ELLORA THERAPEUTICS, INC. 2023-07-06 US disclosed
US-20230212127-A1 LIVER X RECEPTOR (LXR) MODULATORS ELLORA THERAPEUTICS, INC. 2023-07-06 US disclosed
US-20220388963-A1 LIVER X RECEPTOR (LXR) MODULATORS ELLORA THERAPEUTICS INC (US) 2022-12-08 US disclosed
US-20220106274-A1 LIVER X RECEPTOR (LXR) MODULATORS ELLORA THERAPEUTICS, INC. 2022-04-07 US disclosed
US-11034657-B2 Liver X receptor (LXR) modulators ELLORA THERAPEUTICS, INC. (US) 2021-06-15 US disclosed
US-11034657-B2 Liver X receptor (LXR) modulators ELLORA THERAPEUTICS, INC. (US) 2021-06-15 US disclosed
EP-3041835-B1 LIVER X RECEPTOR (LXR) MODULATORS ELLORA THERAPEUTICS INC (US) 2020-04-08 EP disclosed
EP-3626712-A2 LIVER X RECEPTOR (LXR) MODULATORS Ellora Therapeutics, Inc. (US) 2020-03-25 EP disclosed
EP-3626712-A2 LIVER X RECEPTOR (LXR) MODULATORS Ellora Therapeutics, Inc. (US) 2020-03-25 EP disclosed
US-20190169131-A1 LIVER X RECEPTOR (LXR) MODULATORS RALEXAR THERAPEUTICS, INC. 2019-06-06 US disclosed
US-20160221956-A1 Liver X Receptor (LXR) Modulators ALEXAR THERAPEUTICS, INC. (US) 2016-08-04 US disclosed
US-20160221956-A1 Liver X Receptor (LXR) Modulators ALEXAR THERAPEUTICS, INC. (US) 2016-08-04 US disclosed
US-20160221956-A1 Liver X Receptor (LXR) Modulators ALEXAR THERAPEUTICS, INC. (US) 2016-08-04 US disclosed
US-20160214943-A1 Liver X Receptor (LXR) Modulators RALEXAR THERAPEUTICS, INC. 2016-07-28 US disclosed
US-20160214943-A1 Liver X Receptor (LXR) Modulators RALEXAR THERAPEUTICS, INC. 2016-07-28 US disclosed
US-20160214943-A1 Liver X Receptor (LXR) Modulators RALEXAR THERAPEUTICS, INC. 2016-07-28 US disclosed
EP-3041834-A1 LIVER X RECEPTOR (LXR) MODULATORS Alexar Therapeutics, Inc. (US) 2016-07-13 EP disclosed
WO-2015035027-A1 LIVER X RECEPTOR (LXR) MODULATORS ALEXAR THERAPEUTICS, INC. (US) 2015-03-12 WO disclosed
WO-2015035027-A1 LIVER X RECEPTOR (LXR) MODULATORS ALEXAR THERAPEUTICS, INC. (US) 2015-03-12 WO disclosed
WO-2015035015-A1 LIVER X RECEPTOR (LXR) MODULATORS ALEXAR THERAPEUTICS, INC. (US) 2015-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160214943-A1 Liver X Receptor (LXR) Modulators NR1H2, NR1H3, RXRB NR1H2 1/4885MARS1 3622/4885MDM2 3331/4885
US-20220106274-A1 LIVER X RECEPTOR (LXR) MODULATORS NR1H2, NR1H3, NR1H4 NR1H2 1/4885MARS1 2842/4885MDM2 4638/4885
US-20160221956-A1 Liver X Receptor (LXR) Modulators NR1H2, NR1H3, NR1H4 NR1H2 1/4885MARS1 2842/4885MDM2 4638/4885
US-20190169131-A1 LIVER X RECEPTOR (LXR) MODULATORS NR1H2, NR1H3, NR1H4 NR1H2 1/4885MARS1 2842/4885MDM2 4638/4885
US-11034657-B2 Liver X receptor (LXR) modulators NR1H2, NR1H3, NR1H4 NR1H2 1/4885MARS1 2842/4885MDM2 4638/4885
US-20220388963-A1 LIVER X RECEPTOR (LXR) MODULATORS NR1H2, NR1H3, NR1H4 NR1H2 1/4885MARS1 2842/4885MDM2 4638/4885
US-20230212127-A1 LIVER X RECEPTOR (LXR) MODULATORS NR1H2, NR1H3, NR1H4 NR1H2 1/4885MARS1 2719/4885MDM2 4565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.